Investor Dashboard

News Releases

Date Title and Summary Additional Formats
Toggle Summary NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering EDINBURGH, United Kingdom , Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the
View HTML
Toggle Summary NuCana Presents Three Posters at the ESMO Virtual Congress 2020
Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302) NUC-3373’s Favorable Pharmacokinetic and Safety Profile Unaffected by Leucovorin First-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a
View HTML
Toggle Summary NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
EDINBURGH, United Kingdom , Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889
View HTML
Toggle Summary NuCana Announces Pricing of a Public Offering of American Depositary Shares
EDINBURGH, United Kingdom , Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares
View HTML
Toggle Summary NuCana Announces Proposed Public Offering of American Depositary Shares
EDINBURGH, United Kingdom , Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary
View HTML
Toggle Summary NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update
EDINBURGH, United Kingdom , Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
View HTML
Toggle Summary NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference
EDINBURGH, United Kingdom , May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference .
View HTML
Toggle Summary NuCana Reports First Quarter 2020 Financial Results and Provides Business Update
Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic Numerous Clinical Data Announcements Expected in 2020 Cash and Cash Equivalents Expected to Fund Operations At Least into the Fourth Quarter of 2021 EDINBURGH, United Kingdom , May 19, 2020
View HTML
Toggle Summary NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic
EDINBURGH, United Kingdom , May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its global
View HTML
Toggle Summary NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells NUC-3373 Induces Endoplasmic Reticulum Stress and Release of DAMPs in Colorectal Cancer Cells
View HTML